Payment overview · 2025
General Payments
$68.63
4 reported records · 3 companies
Healthcare provider profile · identity verified
Priscilla Jean Benner, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PENNSBURG, PA · NPI 1629078936
Verified facts
What the public records show
CMS Open Payments records show Priscilla Jean Benner, M.D. received $68.63 in general payments during 2025 across 4 reported records.
Exact Sciences Corporation accounted for 58.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.09 | 58.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.86 | 21.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.68 | 19.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $68.63 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $40.09 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.68 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
67 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 394 | 111 |
| Losartan Potassium | Losartan Potassium | 370 | 107 |
| Metoprolol Succinate | Metoprolol Succinate | 356 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 307 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 265 | 70 |
| Furosemide | Furosemide | 199 | 58 |
| Lisinopril | Lisinopril | 163 | 53 |
| Simvastatin | Simvastatin | 118 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 115 | 39 |
| Eliquis | Apixaban | 102 | 22 |
| Metformin Hcl | Metformin Hcl | 101 | 33 |
| Omeprazole | Omeprazole | 99 | 39 |
| Lorazepam | Lorazepam | 97 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 29 |
| Famotidine | Famotidine | 81 | 20 |
| Gabapentin | Gabapentin | 76 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 27 |
| Xarelto | Rivaroxaban | 72 | 13 |
| Trazodone Hcl | Trazodone Hcl | 71 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 19 |
| Synthroid | Levothyroxine Sodium | 67 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 65 | 22 |
| Glimepiride | Glimepiride | 64 | 22 |
| Metformin Hcl Er | Metformin Hcl | 64 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 61 | 19 |
| Montelukast Sodium | Montelukast Sodium | 58 | 17 |
| Bupropion Xl | Bupropion Hcl | 56 | 16 |
| Ezetimibe | Ezetimibe | 56 | 22 |
| Spironolactone | Spironolactone | 56 | 14 |
| Clonazepam | Clonazepam | 55 | suppressed |
| Mounjaro | Tirzepatide | 55 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 55 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 49 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 29 |
| Baclofen | Baclofen | 45 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 45 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 11 |
| Lovastatin | Lovastatin | 42 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 42 | suppressed |
| Topiramate | Topiramate | 42 | suppressed |
| Allopurinol | Allopurinol | 40 | 14 |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 40 | 14 |
| Alendronate Sodium | Alendronate Sodium | 39 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 39 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 13 |
| Jardiance | Empagliflozin | 33 | suppressed |
| Fenofibrate | Fenofibrate | 32 | 14 |
| Meloxicam | Meloxicam | 31 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Valsartan | Valsartan | 31 | 11 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 30 | 30 |
| Januvia | Sitagliptin Phosphate | 30 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 30 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 23 |
| Torsemide | Torsemide | 29 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 28 | 28 |
| Potassium Chloride | Potassium Chloride | 28 | suppressed |
| Budesonide | Budesonide | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Carvedilol | Carvedilol | 26 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Lacosamide | Lacosamide | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Loperamide | Loperamide Hcl | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Prednisone | Prednisone | 23 | suppressed |
| Clobazam | Clobazam | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Konvomep | Omeprazole/Sodium Bicarbonate | 14 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Xopenex Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Rufinamide | Rufinamide | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $68.63 · 4 records | Exact Sciences Corporation | Cologuard Collection Kit, MOUNJARO, VRAYLAR, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error